Compare GSL & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | NUWE |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | Greece | United States |
| Employees | 7 | 38 |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7M |
| IPO Year | N/A | N/A |
| Metric | GSL | NUWE |
|---|---|---|
| Price | $37.71 | $1.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $43.50 | N/A |
| AVG Volume (30 Days) | ★ 236.8K | 30.8K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.14 |
| Revenue Next Year | N/A | $18.51 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.92 | $0.19 |
| 52 Week High | $41.40 | $25.95 |
| Indicator | GSL | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 47.43 |
| Support Level | $36.82 | $0.96 |
| Resistance Level | $38.52 | $1.24 |
| Average True Range (ATR) | 0.94 | 0.09 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 14.50 | 63.06 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.